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ABSTRACT
To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-
adjusted oral busulfan plus cyclophosphamide (targeted BUCY). The starting dose of THY was 4.5 mg/kg
given over days 3, 2, and 1, escalated in steps of 1.5 mg/kg in cohorts of 15 evaluable patients. Escalation
was dependent on acute GVHD incidence and Epstein-Barr virus reactivation. Fifty-six patients with myelo-
dysplastic syndrome and other myeloid disorders underwent transplantation with peripheral blood progenitor
cells from related (n  30) or unrelated (n  26) donors. All but 2 patients achieved engraftment, and 56%
survived in remission beyond 1 year. The incidence of acute GVHD was 50%, and that of chronic GVHD was
34%. The highest THY dose was 6.0 mg/kg, a dose at which 1 patient experienced Epstein-Barr virus
reactivation. Nine patients did not receive the prescribed THY dose. Results were comparable for related and
unrelated transplants and for patients given 4.5 or 6.0 mg/kg THY. Among 27 myelodysplastic syndrome
patients (14 with related and 13 with unrelated donors) who underwent transplantation concurrently with
targeted BUCY without THY, the incidence of acute and chronic GVHD was 82%. Thus, THY 4.5 to 6.0
mg/kg seemed beneficial for GVHD prevention in BUCY-conditioned patients who underwent transplantation
with peripheral blood progenitor cells, although relapse-free survival did not differ significantly from that in
comparable historical controls not given THY.
© 2006 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Allogeneic hematopoietic cell transplantation
HCT) is currently the only therapy with curative
otential for myelodysplastic syndrome (MDS) and
yeloproliferative disorders. Depending on the dis-
ase state at the time of transplantation, 40% to 70%
f patients survive long-term in remission and are
robably cured of their disease [1-3]. The results with
ransplants from unrelated donors selected for HLA
dentity on the basis of high-resolution typing are s
B&MTpproaching those achieved with HLA genotypically
dentical sibling transplants, thus making this treat-
ent available to more patients [1]. However, graft-
ersus-host disease (GVHD) has remained a major
roblem in patients both with related and unrelated
onors, affecting as many as 70% to 80% of patients
nd causing considerable morbidity and mortality, of-
en related to infections. In addition, among patients
ith more advanced disease, posttransplantation re-
apse is a frequent complication [1,3-5]. In several
tudies, intensiﬁcation of the conditioning regimens
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5as reduced relapse rates, but generally at the expense
f a higher incidence of regimen-related toxicity and
ortality [6,7]. Furthermore, the cumulative inci-
ence of GVHD tends to be higher with more inten-
ive conditioning regimens [8,9], and intensiﬁcation of
VHD prophylaxis—for example, by in vitro T-cell
epletion of the transplant inoculum—has been asso-
iated with an increase in the posttransplantation re-
apse rate [10].
Several transplant teams [11-14] incorporated
he rabbit antihuman thymocyte globulin Thymo-
lobulin (THY) Genzyme, Cambridge, MA into
onditioning regimens and observed a lower inci-
ence of GVHD than with otherwise comparable
egimens without THY. Some reports also sug-
ested that even if GVHD developed, treatment
as more successful [14]. We therefore conducted a
rospective trial in patients with high-risk myeloid
isorders, using a well-established conditioning
able 1. Patient and Disease Characteristics
Variable tBUCY/THY 
o. patients studied 56
atient age, y, range (median) 9-65 (50)
ex (M/F) 24/32
iagnosis
RA 4*
RARS —
RAEB 14‡
AML 17§
MDS (NOS) 3
ICMF 8¶
Other MPD 6¶#
CMML 4**††
nterval from diagnosis to transplantation,
mo, range (median) 1.5-318 (6.1)
omorbidity score (HCT-CI), range (median) 0-7 (1)
ML indicates acute myelogenous leukemia; CMML, chronic myel
myeloid metaplasia); MDS, myelodysplastic syndrome; MPD, m
anemia; RAEB, RA with excess blasts; RARS, RA with ringe
Thymoglobulin; HCT-CI, hemopoietic cell transplantation co
then).
All had intermediate- or high-risk cytogenetics by International Pr
intermediate 2 risk; 1 patient had refractory cytopenia with multili
Six patients were classiﬁed as low risk and 21 as intermediate 1 ris
karyotypes. By WHO criteria, 8 patients had RA, 12 had RCM
had RARS.
By IPSS classiﬁcation, 1 patient was categorized as low risk, and 4
Among these, 2 had good-risk (all normal), 5 intermediate-risk, a
Ten of these had transformed to AML from MDS, and 7 had de n
and 2 with refractory disease). Among the patients with de nov
By IPSS, 2 patients were classiﬁed as intermediate 1 and 1 was cla
All 14 patients with ICMF or other MPD had severe ﬁbrosis [39]
and 11 as intermediate risk [40].
Three patients had a history of polycythemia vera and 2 of essentia
not be classiﬁed.
*One patient was simultaneously diagnosed with chronic lymphoc
†Using the criteria of the M.D. Anderson classiﬁcation, 2 patie
(karyotypes were normal, 8, 20q, and complex, respectively74egimen (oral busulfan [BU] targeted to steady-state
lasma levels of 800-900 ng/mL given over 4 days,
ollowed by cyclophosphamide [CY] 60 mg/kg on 2
onsecutive days [1]) to which THY was added on
ays 3, 2, and 1 before transplantation in a
ose-escalation design. The purpose was to deter-
ine the optimum dose of THY for GVHD pre-
ention without increasing the risk of relapse and
nfections. In a parallel study, patients with low-risk
DS were conditioned with an identical BUCY
egimen but did not receive THY. We report here
he results of both trials and compare them with
hose in a historical control group.
ATIENTS AND METHODS
atients
Patient and disease characteristics are summarized
n Table 1.
Regimen
CY (Concurrent Control) tBUCY (Historical Controls) [1]
27 93
11-64 (51) 7-66 (47)
17/10 45/48
26† 55
1† 2
— 20
— 10
— —
— —
— 4
— 2
3.5-146 (11.8) 1-128 (10)
0-4 (1) NA
cytic leukemia; ICMF, idiopathic chronic myeloﬁbrosis (agnogenic
oliferative disorder; NOS, not otherwise speciﬁed; RA, refractory
oblasts; tBUCY, targeted busulfan  cyclophosphamide; THY,
ity index [33]; NA, not available (HCT-CI developed only since
ic Scoring System (IPSS) criteria; 3 were intermediate 1, and 1 was
ysplasia (RCMD) by World Health Organization (WHO) criteria.
SS; 19 patients had good-risk (14 normal) and 8 intermediate-risk
tients had MDS-U undeﬁned as per WHO criteria, and 1 patient
lassiﬁed as intermediate 1, 6 as intermediate 2, and 3 as high risk.
igh-risk karyotypes; 8 had RAEB1 and 6 RAEB2 by WHO criteria.
L (4 in ﬁrst complete remission, 1 in second complete remission,
, 6 had normal karyotypes, and 1 had a complex karyotype.
as high risk; 2 had normal and 1 complex cytogenetics.
criteria of the Lille classiﬁcation, 3 patients qualiﬁed as good risk
bocythemia; 1 patient showed 5% marrow myeloblasts and could
kemia.
low-risk and 1 each had intermediate 2 and high-risk CMMLtBU
omono
yelopr
d sider
morbid
ognost
neage d
k by IP
D, 6 pa
were c
nd 7 h
ovo AM
o AML
ssiﬁed
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Thymoglobulin and Chronic GVHD
Bargeted BUCY  THY (Protocol 1)
From November 2002 through August 2004, 56
atients (24 male and 32 female), 9 to 63 years
median, 50 years) of age, were enrolled. The inter-
al from diagnosis to transplantation was 1.5 to 318
onths (median, 6.1 months). There were 31 pa-
ients with a diagnosis of MDS (see Table 1 for
ategories), including 10 who had transformed to
cute myeloid leukemia (AML); 14 patients with
yeloproliferative disorders; 7 patients with de
ovo AML; and 4 patients with chronic my-
lomonocytic leukemia.
argeted BUCY (Protocol 2; Referred to as
oncurrent Control)
From December 2001 through May 2004, 27 pa-
ients (17 male and 10 female), 11 to 64 years (median,
1 years) of age, with low-risk MDS were enrolled
see Table 1 for categories). The interval from diag-
osis to transplantation was 3.5 to 146 months (me-
ian, 11.8 months). None of the patients had high-risk
ytogenetic ﬁndings, as deﬁned by the International
rognostic Scoring System [15].
istorical Controls
In addition, we used for comparison data from 93
istorical control patients conditioned with targeted
UCY (tBUCY) who were reported previously [1].
hese patients were 7 to 66 years (median, 47 years)
ld, 45 were male, and 48 were female. The interval
rom diagnosis to transplantation was 1 to 128 months
median, 10 months). The diagnoses are listed in Ta-
le 1. Comorbidity indices were not available on those
atients.
onditioning Regimens
The conditioning regimens are summarized in
able 2.
argeted BUCY  THY
Patients were prepared with a regimen of oral BU
t a starting dosage of 1 mg/kg to be given every
hours for 16 doses on days 7 to 4, followed by
Y intravenously 60 mg/kg/d on days 3 and 2.
henytoin was given as prophylaxis for potential
U-induced seizures as described previously [16]. De-
ails of the chemical and pharmacokinetic analysis of
U to provide accurate assessment of BU exposure
uring conditioning have been described previously
17]. Blood samples were collected at 0, 1, 2, 4, and 6
ours after the morning doses on days 1, 2, and 3, and
ubsequent doses were adjusted to achieve steady-state
lasma levels in the range of 800 to 900 ng/mL, as [
B&MTescribed previously [16]. No dose adjustments for
Y were made. On days 3, 2, and 1, patients
eceived THY intravenously. The starting dose of
HY was 4.5 mg/kg total (0.5 mg/kg on day 3 and
mg/kg each on days 2 and 1). Plasma samples
ere obtained before the ﬁrst dose of THY, 1 hour
fter completion of the third dose, and in the morning
fter the completion of hematopoietic stem cell infu-
ion (day 1).
Patients were enrolled in cohorts of 15, with THY
tarting at a dose of 4.5 mg/kg. If 5 patients devel-
ped acute GVHD grades II to IV and no patient
howed reactivation of Epstein-Barr virus (EBV), as
etermined by an increase in DNA copies in blood
lasma to 1000/mL, then the next cohort was to
eceive the same dose of THY. If 5 patients devel-
ped acute GVHD, then the dose was to be increased
o 6 mg/kg. The next cohort of 15 was to receive a
ose of 7.5 mg/kg or the same dose (6 mg/kg), de-
ending on the frequencies of GVHD and EBV reac-
ivation, a complication reported in one earlier study
able 2. Donor and Transplant Characteristics
Variable
Regimen
tBUCY/THY tBUCY
onor age, y, range (median) 8-63 (42) 27-69 (40)
onor sex (M/F) 29/27 12/15
onor/patient relationship
HLA-identical sibling 30 14
Unrelated volunteer 26* 13†
ource of stem cells
Bone marrow 1‡ 0
Peripheral blood 55 27
onor/patient CMV serology
/ 16 10
/ 8 3
/ 16 5
/ 16 9
onditioning
Targeted BUCY 56 27
Thymoglobulin
4.5 mg/kg 15 0
6.0 mg/kg 32§ 0
Incomplete dose (0.5-3.5 mg/kg) 9 0
VHD prophylaxis MTX/CSP 56 27
MV indicates cytomegalovirus; CSP, cyclosporine; MTX, meth-
otrexate; tBUCY, targeted busulfan  cyclophosphamide;
THY, Thymoglobulin.
Among these, 3 were 1 allele–mismatched with the patient (see
text).
Among these, 3 were 1 antigen– or 1 allele–mismatched with the
patient (see text).
Donor refused G-CSF administration.
In the ﬁrst cohort of 15 patients who received the prescribed dose
of 6 mg/kg, 1 patient showed a titer increase of Epstein-Barr
virus DNA copies in plasma1000; per protocol, this prevented
a further dose escalation of THY, and subsequent patients were
treated at doses of 6 mg/kg. No further Epstein-Barr virus
activation was observed.18].
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5argeted BUCY
Patients received the same regimen of tBUCY as
escribed previously, but without the addition of
HY.
onors and Source of Stem Cells
Donor characteristics are summarized in Table 2.
mong 56 patients prepared with tBUCY plus THY,
0 received transplants from genotypically HLA-iden-
ical siblings, and 26 from unrelated donors. All sib-
ing pairs were identical for HLA-A, -B, -C, and
DQB1 by intermediate-resolution typing and for
DRB1 by sequencing. For unrelated transplants, all
atients and donors had DNA sequenced for HLA-A,
B, -C, and -DRB1 and had intermediate-resolution
yping for -DQB1, except for 4 donors who had se-
uencing at -A, -B, and -DRB1 but intermediate-
esolution typing for -C and -DQB1. Three donors
ere mismatched with the patient for a single allele
-B, -A, or -DQB1); all others were HLA identical. All
atients but 1 received granulocyte colony-stimulating
actor (G-CSF)–mobilized peripheral blood progeni-
or cells (PBPCs).
Among 27 concurrent controls prepared with
BUCY and no THY, 14 received transplants from
enotypically HLA-identical siblings, and 13 from un-
elated donors (all had DNA sequenced at HLA-A, -B,
C, and -DRB1 with intermediate-resolution typing
or -DQB1). Three were mismatched with the patient
1 for a -DRB1 antigen and 2 for a -B allele), and 10
ere HLA identical to the patient. All patients were
iven G-CSF–mobilized PBPCs.
VHD Prophylaxis and Therapy
Prophylaxis for GVHD, in addition to the pre-
ransplantation administration of THY, consisted of
ethotrexate given at 10 mg/m2 on days 1, 3, 6, and
1 and cyclosporine (CSP) starting on day 1 and, in
he absence of GVHD, continued on a daily basis until
ay 180 as described previously [19]. If GVHD was
resent, CSP was continued beyond day 180 for as
ong as necessary. The diagnoses of acute and chronic
VHD were made by established criteria [20]. Meth-
lprednisolone (or prednisolone) was given as ﬁrst-
ine therapy. Steroid-refractory GVHD was treated
ccording to protocols active at the time of the pa-
ients’ transplantations.
ngraftment and Rejection
The day of engraftment was deﬁned as the ﬁrst of
consecutive days on which the neutrophil count
xceeded 0.5 109/L [21]. Evidence of graft rejection
as sought when the absolute neutrophil count failed
o reach 0.5  109/L, when the absolute neutrophil
ount declined after initial recovery, and when relapse G
76as diagnosed. Patients who died before day 28 were
ot evaluated for engraftment. When the donor and
atient were of different sexes, engraftment was veri-
ed by testing bone marrow and peripheral blood
ononuclear cells with ﬂuorescence in situ hybridiza-
ion with Y or X chromosome–speciﬁc probes [22,23].
hen patient and donor were of the same sex, DNA
rom marrow and peripheral blood mononuclear cells
as ampliﬁed for several variable number tandem re-
eat loci for identiﬁcation of informative host and
onor markers [24].
elapse
All patients had marrow samples examined mor-
hologically and by cytogenetic and ﬂow cytometric
nalyses on days 28 and 84 after transplantation and
hen annually or as clinically indicated. Relapse was
eﬁned morphologically by marrow dysplasia and cy-
ogenetically by the detection of metaphases in the
arrow that showed the same clonal marker(s) as
dentiﬁed before transplantation (or by ﬂuorescence in
itu hybridization markers, if appropriate) or by the
eemergence of myeloblasts or aberrant precursors
dentiﬁed by ﬂow cytometry [25].
nfections
Blood samples were examined weekly for evidence
f cytomegalovirus (CMV) antigenemia [26]. Intersti-
ial pneumonia was diagnosed on the basis of radio-
raphic ﬁndings; by use of culture, histologic, or his-
ochemical analysis of bronchoalveolar lavage ﬂuid; by
pen lung biopsy; or at autopsy [27]. Strategies to
revent infectious diseases included the prophylactic
r preemptive use of systemic antibiotics, ﬂuconazole,
cyclovir, and ganciclovir (or foscarnet) [28]. All
MV-seronegative patients received CMV-negative
r leukocyte-depleted blood products. Acyclovir pro-
hylaxis was given to all patients who were seroposi-
ive for herpes simplex or herpes zoster virus. Plasma
amples were also monitored twice weekly (through
ay 42) for EBV DNA in plasma, and treatment with
ituximab was given if the titer increased to 1000
opies per milliliter [29].
auses of Death
Deaths that occurred after progression or recur-
ence of the underlying disease were categorized as
ue to disease recurrence, regardless of the proximate
auses; deaths in the absence of relapse were catego-
ized as nonrelapse mortality. Infection was consid-
red the cause of death when a bacterial, viral, or
ungal infection other than interstitial pneumonia was
he proximate cause of death in patients who had not
elapsed. Infections were further categorized accord-
ng to whether or not they were associated with
VHD and with organ failure. Multiorgan failure was
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Thymoglobulin and Chronic GVHD
Bonsidered the cause of death if decompensation oc-
urred in at least 2 organ systems (eg, liver and kidneys
r liver and lungs) and could not be attributed to
VHD or infection alone.
tatistical Methods
The probabilities of survival and relapse-free sur-
ival were estimated by using the Kaplan-Meier
ethod. The incidence rates of relapse, acute and
hronic GVHD, nonrelapse mortality, and infection
ere expressed in terms of cumulative incidence [30].
ox regression was used to analyze risk factors related
o the hazards for these outcomes. In these analyses,
ortality was considered a competing risk for all other
utcomes, and relapse was a competing risk for non-
elapse mortality. The effect of THY doses on serum
evels of THY was analyzed by the Wilcoxon rank sum
est.
To put these results into perspective, outcomes
ere also compared with previously reported results in
atients with MDS or myeloproliferative disease in
arious risk categories conditioned with tBUCY with-
ut the use of THY (historical controls) [1]. Data were
nalyzed as of August 31, 2004.
ESULTS
onditioning
The target range for steady-state plasma levels of
U was 800 to 900 ng/mL. The actual BU steady-
tate concentration levels reached in patients condi-
ioned with tBUCY plus THY were 734 to 1081
g/mL (median, 874 ng/mL). The median total dose
f BU administered was 14.9 mg/kg (range, 9.8-22.4
g/kg). Among the 27 concurrent patients prepared
ith tBUCY, BU steady-state concentration levels
ere 776 to 1074 ng/mL (median, 921 ng/mL). The
edian total dose of BU administered was 14.2 mg/kg
range, 11.2-19.8 mg/kg).
The starting dose of THY was 4.5 mg/kg (over 3
ays) for a cohort of 15 patients. Two patients did not
eceive the prescribed dose (because of severe chills
nd patient preference). Thus, 17 patients were en-
olled in this cohort. None showed EBV reactivation,
ut 7 of 15 evaluable patients required treatment for
cute GVHD, and the THY dose was increased to
mg/kg. To arrive at 15 evaluable patients in this
ohort, 20 patients had to be enrolled, because 5 did
ot receive the prescribed dose of THY (because of
ypotension or patient decision in 1 patient each and
ttending physician preference in 3). One of 15 pa-
ients given the complete dose of THY experienced
BV reactivation. Thus, there was no further dose
scalation of THY, and 19 additional patients were
nrolled, 17 of whom received THY at 6 mg/kg,
hereas in 2, the dose on day 1 was not given o
B&MTbecause of hypotension and patient preference, re-
pectively).
In 42 patients who received the prescribed dose of
HY, we also determined serum levels of THY by
sing an assay developed by Genzyme (Cambridge,
A). Levels in samples obtained upon completion of
he last dose of THY (day1) were 3.9 to 80.1 g/mL
median, 29.3 g/mL) for total THY and 0.2 to 7.2
g/mL (median, 2.3 g/mL) for “active” THY, de-
ned as the amount that was available for binding to
ymphocytes, as determined by ﬂow cytometry [31].
he corresponding levels after completion of PBPC
nfusions (day 1) were 10.2 to 68.8 g/mL (median,
9.8 g/mL) and 0.5 to 4.2 g/mL (median, 1.9 g/
L), respectively. In patients given 4.5 mg/kg THY,
he median level on day 1 was 24.7 g/mL for total
nd 2.0 g/mL for active THY; the corresponding
evels in patients given 6.0 mg/kg were 40.9 and 2.8
g/mL, respectively. The differences at each dose
evel were signiﬁcant (P  .02 and .03, respectively).
evels obtained after the completion of PBPC infu-
ion (day 1) also tended to be higher among patients
ho received the higher dose of THY, but differences
ere not signiﬁcant (not shown).
ngraftment
Among tBUCY  THY–treated patients, 2 died
on days 19 and 22, respectively) and could not be
valuated for engraftment. Among the remaining 54
atients, 1 with an HLA-identical sibling donor, and 1
ith an unrelated donor did not have sustained en-
raftment. All concurrent control patients prepared
ith tBUCY survived beyond day 28 and achieved
ustained engraftment.
raft-versus-Host Disease
Results are illustrated in Figure 1. Among patients
reated with tBUCY  THY, 52 (24 with unrelated
nd 28 with HLA-identical sibling donors) were eval-
ated for acute GVHD (Figure 1A). Overall, 30 pa-
ients (16 unrelated and 14 related transplant recipi-
nts) developed acute GVHD (grades II-IV)
ecessitating therapy, for a cumulative incidence of
0% (by day 100). Among the 44 patients who re-
eived the prescribed dose of THY, 9 of 22 with
elated and 14 of 22 with unrelated donors required
herapy for acute GVHD, for an overall incidence of
4%. Among 8 evaluable patients who did not receive
he prescribed dose of THY (1 of these did not achieve
ngraftment), 7 (88%) required therapy for GVHD.
he cumulative incidence of chronic GVHD at 1 year
as 34% (31% among patients who had received the
rescribed dose of THY). The incidence of chronic
VHD by THY dose is shown in Figure 1B. There
as no signiﬁcant difference in the incidence of acute
r chronic GVHD between patients treated with 4.5
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5r 6.0 mg/kg THY. There was also no difference with
egard to the severity of GVHD between the 2
roups.
Among concurrent patients conditioned with
BUCY without THY, 11 (79%) of 14 with sibling
onors and 11 (85%) of 13 with unrelated donors
eveloped acute GVHD necessitating therapy. Exten-
ive chronic GVHD requiring therapy developed in
2% of patients. One patient in this study had neither
cute nor chronic GVHD.
urvival
One-year relapse-free survival was 56% among
he 56 patients with more advanced myeloid malig-
ancies who were conditioned with tBUCY  THY
nd was 78% in concurrent controls (all patients with
ood-risk MDS) conditioned with tBUCY only.
mong patients who survived beyond 1 year, there
ere no signiﬁcant differences in the Karnofsky per-
ormance scores between tBUCY/THY-conditioned
nd tBUCY-conditioned concurrent controls, al-
igure 1. Cumulative incidence of GVHD: acute (A) and chronic
B). Shown separately are the incidences for patients given the
rescribed doses of 4.5 or 6.0 mg/kg THY and patients who did not
eceive the prescribed dose (THY 4.5 mg/kg). The overall inci-
ence of acute GVHD (grades II-IV) was 50%, and the overall
ncidence of extensive chronic GVHD was 34%.hough only 2 (6%) of 31 tBUCY/THY-conditioned *
78atients had scores of 80, compared with 5 (24%) of
1 patients not given THY.
elapse
The tBUCY  THY protocol enrolled patients
ith advanced or high-risk MDS, myeloproliferative
isorders, and AML. Twelve of the 56 patients had
isease recurrence, for a cumulative incidence of 21%.
he corresponding incidence rates for patients who
eceived 4.5 mg/kg versus 6.0 mg/kg versus 4.5
g/kg (incomplete dose) THY were 20%, 13%, and
4%, respectively. Among patients with refractory
nemia with excess blasts, the cumulative incidence of
elapse at 1 year was 35%, compared with 24% for
atients with AML and 14% for patients with myelo-
roliferative disorders. There was a trend for BU
evels 800 ng/mL to be associated with a higher
elapse rate than with levels 800 ng/mL (hazard
atio, 3.5; P  .17). All concurrent controls condi-
ioned with tBUCY without the addition of THY had
ood-risk MDS (5% marrow myeloblasts and no
igh-risk cytogenetics), and none experienced disease
ecurrence.
onrelapse Mortality
Causes of death are listed in Table 3. Among
atients conditioned with tBUCYTHY, nonrelapse
ortality was 12.5% at day 100 and 23% at 1 year.
here was no difference between cohorts who had
eceived different doses of THY. Similarly, nonre-
apse mortality was not affected by plasma BU levels.
able 3. Causes of Death*
Cause of Death
Regimen
tBUCY/THY tBUCY
Related URD Related URD
elapse 2 3 — —
ulmonary
Pneumonia — — 1 —
DAD/MOF — — — —
Aspergillus — 1 1 1
Viral 2 — — —
Respiratory
failure/ARDS/IPS 1 3 — 1
OF — 2 — —
OD 1 — — —
ardiac — — 2 —
VHD 1 1 — 1
uicide — — 1 —
otal 7 10 5 4
RDS indicates acute respiratory distress syndrome; DAD, diffuse
alveolar damage; GVHD, graft-versus-host disease; IPS, inter-
stitial pneumonitis syndrome; MOF, multiorgan failure;
tBUCY, targeted busulfan cyclophosphamide; THY, Thymo-
globulin; URD, unrelated donor; VOD, veno-occlusive disease
of the liver (sinusoidal obstruction syndrome).With follow-up of 12 to 42 months.
O
p
a
c
t
a
6
r
c
s
t
t
V
o
i
e
t
m
v
c
o
a
r
T
p
2
W
d
c
w
s
T
c
r
a
d
O
o
6
w
ﬁ
p
p
4
1
f
w
d
g
w
d
E
a
c
i
C
c
c
a
C
G
t
d
r
(
C
a
e
a
T
[
c
F
o
a
w
i
T
C
C
C
D
Thymoglobulin and Chronic GVHD
Bverall 17 patients have died, including 5 with disease
rogression/relapse, at 19 to 262 days (median, 75 days)
fter transplantation. Other than relapse, the major
auses of death were organ toxicity and infections.
Among concurrent controls conditioned with
BUCY, the nonrelapse mortality was 3.7% at day 100
nd 22% at 1 year. Overall, 9 patients have died, 75 to
39 days (median, 255 days) after HCT. Other than
elapse (related to advanced disease stage in patients
onditioned with tBUCY  THY), there were no
igniﬁcant differences in causes of death between
BUCY  THY–treated patients and concurrent con-
rols.
iral Reactivation
Epstein-Barr virus. An increase in the plasma titer
f EBV DNA to 1000 copies per milliliter occurred
n 1 patient (given 6 mg/kg of THY). There was no
vidence of a lymphoproliferative disorder. The pa-
ient was treated successfully with a single dose of 375
g/m2 of the anti-CD20 antibody rituximab as pre-
iously described by Carpenter et al. [29].
Cytomegalovirus. CMV reactivation tended to oc-
ur earlier in patients who received THY; however,
verall only 18 (32%) of 56 patients reactivated (CMV
ntigenemia), compared with 15 (56%) of 27 concur-
ent controls who did not receive THY (Figure 2).
he proportions of patients with 10 positive cells
er slide (200 000 cells) were comparable in the
groups (4/56 [7%] and 2/27 [7%], respectively).
hereas only 1 seronegative patient with a seronegative
onor became CMV positive (a tBUCY-conditioned
ontrol patient), reactivation after transplantations for
hich the donor, the patient, or both were CMV
eropositive occurred in 18 (45%) of 40 tBUCY 
HY–conditioned patients and 14 (78%) of 18 con-
igure 2. Reactivation of CMV. Shown is the cumulative incidence
f CMV antigenemia in patients conditioned with tBUCY  THY
nd tBUCY (concurrent controls). Low risk: donor and patient
ere seronegative; high risk: donor, patient, or both were seropos-ttive.
B&MTurrent controls. Three patients at high risk for CMV
eactivation, 2 treated with tBUCY  THY (days 14
nd 16) and 1 treated with tBUCY only (day 444),
eveloped CMV disease.
ther Infections
During the ﬁrst 100 days after HCT, bacteremias
ccurred in 42% of patients who received THY and in
0% of concurrent controls not given THY. There
as no difference in the spectrum of bacteria identi-
ed between the 2 groups.
Invasive fungal infections were documented in 3
atients in each group. In tBUCY  THY–treated
atients, Aspergillus species were documented at 1.5 to
.5 months. One patient died from fungal pneumonia,
from problems associated with renal failure, and 1
rom encephalitis and GVHD. In concurrent controls
ho had not received THY, Aspergillus species were
ocumented in 2 (at 3 and 11 months), and Candida
labrata, Aspergillus fumigatus, and Rhizopus species
ere found in 1 patient (at 2 months). Two patients
ied with aspergillus pneumonia, and 1 is surviving.
ffect of Graft Composition on Relapse, GVHD,
nd Survival
Data on the phenotypic composition of the cells
ollected from the transplant donors are summarized
n Table 4. There was a slightly lower proportion of
D3 cells in the transplant inoculum for patients
onditioned with tBUCY  THY than in concurrent
ontrols (P  .07). However, there was no recogniz-
ble effect of the content of CD34, CD3, CD4,
D8, or CD56 cells on the incidence of acute
VHD or nonrelapse mortality. There was a sugges-
ion, however, that higher numbers of CD3/CD56
onor cells were correlated with a lower incidence of
elapse in patients conditioned with tBUCY and THY
hazard ratio, 0.3; P  .07).
omorbid Conditions
nd Transplantation Outcomes
Because comorbid conditions may have a major
ffect on posttransplantation outcome [32], we also
nalyzed results on the basis of comorbidity scores.
he comorbidity score as modiﬁed by Sorror et al.
33] was 0 to 7 (median, 1) for tBUCY  THY–
onditioned patients and 0 to 4 (median, 1) for the
able 4. Graft Composition
Cell Type tBUCY/THY tBUCY
D34 (106/kg) 7.2 (0.1-30.3) 7.6 (3.2-17.2)
D3 (108/kg) 2.0 (0.2-5.8) 2.5 (0.3-4.4)
D3/CD56 (106/kg) 11.3 (0.2-28.0) 12.0 (2.8-59.2)
ata are median (range) of cells infused.BUCY-conditioned concurrent controls. The hazard
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5atio for nonrelapse mortality was higher for patients
ith comorbidity scores of 3 (1.7; conﬁdence inter-
al, 0.6-4.5), but this effect did not reach signiﬁcance
P  .28).
omparison of Results with Historical Controls
The concurrent control group of patients who did
ot receive THY consisted of good-risk patients with
very low relapse risk. Therefore, we also compared
esults in tBUCY  THY–conditioned patients with
hose in a historical control cohort conditioned with
BUCY and composed of patients with good-risk
DS (similar to concurrent controls) and high-risk
DS (comparable to tBUCY  THY–conditioned
atients). Data on relapse-free survival, relapse, and
VHD are summarized in Table 5. Overall, the data
uggest that the addition of THY to a tBUCY regi-
en had a beneﬁcial effect on GVHD (in particular,
hronic GVHD; Figure 3) and, with current follow-
p, did not increase the incidence of disease recur-
ence as compared with historical controls (Figure 4A)
nd resulted in comparable relapse-free survival (Fig-
re 4B). Because these data were not derived from a
able 5. Outcome in Subgroups of Patients Conditioned with tBUCY 
HY (Current Study) and in Concurrent and Historical Controls
End Point
tBUCY/THY
(Current)
tBUCY
(Concurrent
Controls)
tBUCY
(Historical
Controls)
A/RARS (n) NA* 27 57
RFS NA 78% 72%
Relapse NA 0% 5%
Acute GVHD NA 82% 67%
Chronic GVHD NA 82% 40%
AEB (n) 14 — 20
RFS 55% NA 60%
Relapse 35% NA 20%
Acute GVHD 35% NA 75%
Chronic GVHD 42% NA 50%
ML (n) 17 — 10
RFS 58% NA 40%
Relapse 24% NA 30%
Acute GVHD 50% NA 50%
Chronic GVHD 15% NA 30%
dvanced disease (n)† 56 — 36
RFS 56% NA 56%
Relapse 21% NA 19%
Acute GVHD 50% NA 64%
Chronic GVHD 34% NA 47%
ML indicates acute myelogenous leukemia, de novo or evolving
from MDS; RA, refractory anemia; RAEB, RA with excess
blasts; RARS, RA with ringed sideroblasts; RFS, relapse-free
survival; tBUCY, targeted busulfan cyclophosphamide; THY,
Thymoglobulin; NA, not applicable.
Four patients in this study had 5% marrow myeloblasts but
high-risk cytogenetics and were included under “Advanced Dis-
ease.”
All patients conditioned with tBUCY/THY in this study were
considered as having advanced disease (including 4 patients with
5% marrow blasts but with high-risk cytogenetics).s
80andomized study, comparisons must be made with
reat caution. This point is further underscored by the
act that patients in this study received PBPCs as a
ource of stem cells, whereas historical controls un-
igure 4. Outcome in patients conditioned with tBUCY  THY
this study) and in historical controls conditioned with tBUCY
ithout THY. A, Cumulative incidence of relapse. B, Relapse-free
igure 3. Chronic GVHD in tBUCY  THY–conditioned patients
nd in concurrent and historical controls (conditioned with tBUCY).
hown are the cumulative incidences in tBUCY  THY–treated
atients who received the prescribed doses of THY (PBPC, THY,
.5 and 6.0) and tBUCY-conditioned concurrent (PBPC, concur-
ent) and historical controls (Bone Marrow, historical controls).urvival.
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Thymoglobulin and Chronic GVHD
Berwent transplantation with marrow. As illustrated in
igure 3, the incidence of chronic GVHD in patients
ho underwent transplantation with PBPCs after
onditioning with tBUCY  THY was comparable to
hat observed in historical controls who were not
iven THY but who received bone marrow as a source
f stem cells.
ISCUSSION
This study shows that THY at doses of 4.5 to 6
g/kg can be used safely in combination with BU and
Y to condition patients for allogeneic HCT. How-
ver, 15% of patients did not receive the prescribed
ose of THY because of clinically signiﬁcant adverse
eactions or patient and attending physician prefer-
nces. Because the study protocol did not allow for
urther THY dose escalation if a patient experienced
BV reactivation, the maximum THY dose reached
as 6 mg/kg. The cumulative incidence rates of acute
nd chronic GVHD for all evaluable patients were
0% and 34%, respectively. Although the reported
ncidence rates of acute GVHD, particularly for
rades I and II, have shown considerable variation,
omparison to results in concurrent controls condi-
ioned with tBUCY only, without the addition of
HY, suggested a beneﬁcial effect of THY. Such an
ffect seemed to be even stronger for chronic GVHD,
or which incidence rates have shown greater consis-
ency over time [34]. Although the objective of this
tudy was the determination of an optimal THY dose,
e observed no correlation of THY dose and inci-
ence of GVHD, although serum levels correlated
igniﬁcantly with THY doses administered. These ob-
ervations would be consistent with the concept that
he most effective THY levels that could be achieved
ith the current regimen were achieved with the low-
st study dose (4.5 mg/kg). Reassuring was the fact
hat, with the current follow-up, there was no increase
n the incidence of relapse in comparison to historical
ontrols conditioned with tBUCY. Also, although
BV reactivation occurred in a single patient, overall
here was no evidence for an increase in viral reacti-
ation in comparison to patients not given THY. In
act, CMV reactivation occurred in a smaller propor-
ion of THY-treated patients than among concurrent
ontrols not given THY. This pattern was, presum-
bly, related to the lower incidence of GVHD and,
ence, the less frequent use of glucocorticoids in
HY-treated patients.
In contrast to historical controls, patients in this
tudy, with 1 exception, received G-CSF–mobilized
BPCs, which have been associated with an increased
ncidence of GVHD, particularly in its chronic form
35]. Against this background, the current results sug-
est that the use of THY interfered with the develop- G
B&MTent of chronic GVHD and maintained the GVHD
ncidence at a level previously observed with the use of
one marrow as the stem cell source [1]. An interac-
ion between PBPC and THY has also been suggested
y other investigators [36].
In an earlier study, Russell et al. [14] at the Uni-
ersity of Calgary Transplant Center reported an in-
idence of grades II to IV acute GVHD of 8% with
elated and 19% with unrelated donors in patients
ith various diagnoses given THY (4.5 mg/kg) as part
f the conditioning regimen. Nonrelapse mortality
as 5% by day 100, compared with 12.5% in this
tudy. However, the studies are difﬁcult to compare.
he Calgary regimen used ﬂudarabine and BU in-
tead of BUCY for transplantation conditioning. Flu-
arabine is thought to be associated with less nonhe-
atologic toxicity than CY, and it is conceivable that
revention of chemotherapy-induced damage to po-
ential target organs of GVHD, such as the liver and
ntestinal tract, resulted in a lower incidence or fewer
linical manifestations of GVHD. This is consistent
ith the concept that the regimen intensity correlates
ith the development of GVHD [8,9].
Bacigalupo et al. [37] conducted 2 randomized
HY studies that enrolled 109 patients with various
iagnoses who underwent transplantation from unre-
ated donors and compared THY 7.5 and 15 mg/kg
ith patients who did not receive THY. The inci-
ence of GVHD with the lower dose of THY was
omparable to that observed in controls. Among pa-
ients given THY 15 mg/kg, only 11% developed
rades III and IV acute GVHD, compared with 50%
n controls (P  .001). However, the use of the higher
ose of THY was complicated by a high rate of fatal
nfections (30% versus 7% in controls; P  .02).
imilar to the current trial, chronic GVHD developed
n 39% of patients who received THY (at any dose),
ompared with 62% in controls (P  .04). As in this
tudy, there was no improvement in overall or relapse-
ree survival in THY-treated patients.
Remberger et al. [12] reported a matched cohort
tudy of unrelated transplant recipients, 52 of whom
ere conditioned with 10 Gy of single-dose total body
rradiation (TBI) plus CY and 10 mg/kg THY given
n days 5 to 1 (Huddinge) and 104 of whom were
onditioned with 12 to 14.4 Gy of fractionated TBI
nd not given THY (Seattle). THY-treated patients
ad a lower incidence of nonrelapse mortality (P 
005) and overall mortality (P  .03) than patients not
iven THY. Relapse rates were not different. The
uddinge team then presented results in 162 patients
ith hematologic malignancies who were conditioned
ith BUCY or CY/TBI and received transplants from
nrelated donors. Patients received 4, 6, 8, or 10
g/kg THY in addition to CSP and methotrexate as
VHD prophylaxis. The incidence rates of acute
VHD grades II to IV (III/IV) were 29% (15%), 32%
581
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56%), 16% (5%), and 17% (2%) for the 4 dose levels
f THY, respectively. The corresponding rates for
hronic GVHD were 41%, 18%, 46%, and 51%,
espectively. Nonrelapse mortality for the entire
roup was 11% at day 100 and was 17%, 16%, 28%,
nd 25% (P  .03) at 3 years for the 4 THY dose
evels, respectively. Patients given 6 mg/kg THY had
he highest probability of survival. Although the un-
erlying diagnoses varied somewhat among THY
ose groups, the results suggest that increasing the
HY dose beyond 6 mg/kg had no net beneﬁcial
ffect on outcomes.
The day 100 nonrelapse mortality of 12.5% in
atients conditioned with tBUCY  THY in the
resent study was somewhat higher than the 5% re-
orted by the Calgary team, but it was comparable to
he results in the Huddinge study and to our own
istorical data [1]. Considering the limited numbers of
atients in the studies under consideration, conclu-
ions must be drawn with caution.
Also of interest in this study was the observation
hat the dose of CD3/CD56 cells correlated in-
ersely with the probability of relapse (P .07). How-
ver, the study was not designed to further investigate
uch an effect or determine a possible interaction of
HY with CD3/CD56 cells. Finally, the hazard
ate for relapse was 3.5 for patients with steady-state
U levels 800 ng/mL compared with higher levels,
lthough this difference was not signiﬁcant (P  .17).
n effect of BU levels on relapse would be consistent
ith observations in patients with chronic myeloid
eukemia in whom lower steady-state BU levels were
ssociated with an increased incidence of disease re-
urrence after transplantation [16].
Taken together, these data and those reported by
thers [11,13,14] suggest that THY at dosages of 4.5
o 8 mg/kg may reduce the incidence of both acute
nd chronic GVHD after unrelated, and probably
elated, donor transplantation. Of concern is the ob-
ervation that some 15% to 20% of patients showed
oor tolerance of THY, although adverse reactions
ave also been observed with other preparations of
ntithymocyte globulin. Review of the clinical records
lso suggests that, with increasing experience with
HY, premedications can be adjusted such that the
rug is tolerated by most patients.
It is not clear why, despite a reduced incidence of
VHD and no increase in the relapse probability,
elapse-free survival was not improved. In part this
ay be due to limited patient numbers. The observa-
ion also raises the question of whether the results
btained by Russell et al. [14] were related not only to
he use of THY, but also to the combination of THY
ith ﬂudarabine (rather than CY) and BU. Combina-
ions of ﬂudarabine/BU have yielded very encourag-
ng results even without the addition of THY. The
.D. Anderson group, for example, observed a treat-
82ent-related 1-year mortality of 3% among 96 pa-
ients with AML or MDS who were conditioned with
udarabine and intravenous BU and received trans-
lants from related or unrelated donors [2]. At our
enter, we observed a 7% day 100 mortality in an
arlier study in patients with high-risk MDS condi-
ioned with ﬂudarabine and oral BU [38]. These data
uggest that combinations of THY with ﬂudara-
ine/BU regimens deserve to be further explored. The
esults underscore the need for prospective random-
zed trials.
In summary, the present study suggests that incor-
oration of THY in a tBUCY conditioning regimen
ay be beneﬁcial in reducing the incidence of
VHD. So far, this has not caused prohibitive adverse
ffects on relapse or infectious complications. Al-
hough only a very limited dose ﬁnding was possible in
his study, available data suggest an optimal dose of
HY in the range of 4.5 to 8 mg/kg. These observa-
ions warrant further study.
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